Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype – retrospective analysis of Polish Adult Leukemia Group (PALG)

References

• Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92: 2322–2333.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrózek K, Dodge RK, et al. Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–4336.
   PubMed Web of Science ®Google Scholar
• Breems DA, Van Putten WLJ, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26:4791–4797.
   PubMed Web of Science ®Google Scholar
• Wawrzyniak E, Wierzbowska A, Kotkowska A, et al. Different prognosis of acute myeloid leukemia harboring monosomal karyotype with total or partial monosomies determined by FISH: retrospective PALG study. Leuk Res. 2013;37:293–299.
   PubMed Web of Science ®Google Scholar
• Schoch C, Haferlach T, Bursch S, et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer. 2002;35:20–29.
   PubMed Web of Science ®Google Scholar
• Breems DA, Lowenberg B. Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum. Haematologica. 2011;96:491–493.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–365.
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Othus M, Fang M, et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010;116:2224–2228.
   PubMed Web of Science ®Google Scholar
• Perrot A, Luquet I, Pigneux A, et al. Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood. 2011;118:679–685.
   PubMed Web of Science ®Google Scholar
• Xie B, Othus M, Medeiros BC, et al. Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype. Haematologica. 2011;96:631–632.
   PubMed Web of Science ®Google Scholar
• Kayser S, Zucknick M, Dohner K, et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood. 2012;119:551–558.
   PubMed Web of Science ®Google Scholar
• Middeke JM, Beelen D Stadler M, et al. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q. Blood. 2012;120:2521–2528.
   PubMed Web of Science ®Google Scholar
• Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119:2114–2121.
   PubMed Web of Science ®Google Scholar
• Haferlach C, Alpermann T, Schnittger S, et al. Prognostic value of “monosomal karyotype” in comparison to “complex aberrant karyotype” in acute myeloid leukemia: study on 824 cases with aberrant karyotype. Blood. 2012;119:2122–2125.
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: multicenter, randomized phase III study. J Clin Oncol. 2012;10:2441–2448.
   Web of Science ®Google Scholar
• Wierzbowska A, Robak T, Pluta A, et al. Polish Adult Leukemia Group. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008;80:115–126.
   PubMed Web of Science ®Google Scholar
• Budziszewska BK, Pluta A, Sulek K, et al. Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study. Leuk Lymphoma. 2015;56:2331–2338.
   PubMed Web of Science ®Google Scholar
• Shaffer LG, McGovan-Jordan J, Schmid M. ISCN 2013: an international system for human cytogenetic nomenclature. Basel: S. Karger; 2013.
   Google Scholar
• Tavor S, Rothman R, Golan T, et al. Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia. Leuk Lymphoma. 2011;52:642–647.
   PubMed Web of Science ®Google Scholar
• Schanz J, Tüchler H, Sole F, et al. Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia. 2013;27:1988–1995.
   PubMed Web of Science ®Google Scholar
• Lazarevic V, Hörstedt AS, Johansson B, et al. Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood Cancer J. 2014;4:e188.
   PubMed Web of Science ®Google Scholar
• Haferlach C, Dicker F, Herholz H, et al. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia. 2008;22:1539–1541.
   PubMed Web of Science ®Google Scholar
• Nazha A, Kantarjian HM, Bhatt VR, et al. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk. 2014;14:163–171.
   PubMed Web of Science ®Google Scholar
• Gaillard JB, Chiesa J, Reboul D, et al. Monosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion. Leuk Lymphoma. 2012;53:336–337.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Kim HJ, Shin SH, et al. Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation? Biol Blood Marrow Transplant. 2014;20:80–88.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Pabst T, Vellenga E, et al. Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364:1027–1036.
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Ossenkoppele GJ, van Putten W, et al. Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235–1248.
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Grosicki S Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004;18:989–997.
   PubMed Web of Science ®Google Scholar
• Ahn HK, Jang JH, Kim K, et al. Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. Am J Hematol. 2012;87:37–41.
   PubMed Web of Science ®Google Scholar
• Lübbert M, Rüter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97:393–401.
   PubMed Web of Science ®Google Scholar
• Wierzbowska A, Wawrzyniak E, Pluta A, et al. Decitabine improves response rate and prolongs progression free survival in older patients with newly diagnosed acute myeloid leukemia with monosomal karyotype: a subgroup analysis of the DACO-16 trial (abstract). Blood. 2015;126:1336–1336.
   PubMed Web of Science ®Google Scholar